RESUMO
BACKGROUND: Poor-quality life-saving medicines are a major public health threat, particularly in settings with a weak regulatory environment. Insufficient amounts of active pharmaceutical ingredients (API) endanger patient safety and may contribute to the development of drug resistance. In the case of malaria, concerns relate to implications for the efficacy of artemisinin-based combination therapies (ACT). In Papua New Guinea (PNG), Plasmodium falciparum and P. vivax are both endemic and health facilities are the main source of treatment. ACT has been introduced as first-line treatment but other drugs, such as primaquine for the treatment of P. vivax hypnozoites, are widely available. This study investigated the quality of antimalarial drugs and selected antibiotics at all levels of the health facility supply chain in PNG. METHODS AND FINDINGS: Medicines were obtained from randomly sampled health facilities and selected warehouses and hospitals across PNG and analysed for API content using validated high performance liquid chromatography (HPLC). Of 360 tablet/capsule samples from 60 providers, 9.7% (95% CI 6.9, 13.3) contained less, and 0.6% more, API than pharmacopoeial reference ranges, including 29/37 (78.4%) primaquine, 3/70 (4.3%) amodiaquine, and one sample each of quinine, artemether, sulphadoxine-pyrimethamine and amoxicillin. According to the package label, 86.5% of poor-quality samples originated from India. Poor-quality medicines were found in 48.3% of providers at all levels of the supply chain. Drug quality was unrelated to storage conditions. CONCLUSIONS: This study documents the presence of poor-quality medicines, particularly primaquine, throughout PNG. Primaquine is the only available transmission-blocking antimalarial, likely to become important to prevent the spread of artemisinin-resistant P. falciparum and eliminating P. vivax hypnozoites. The availability of poor-quality medicines reflects the lack of adequate quality control and regulatory mechanisms. Measures to stop the availability of poor-quality medicines should include limiting procurement to WHO prequalified products and implementing routine quality testing.
Assuntos
Antimaláricos/análise , Medicamentos Biossimilares/análise , Malária Falciparum/tratamento farmacológico , Malária Vivax/tratamento farmacológico , Amodiaquina/análise , Amodiaquina/normas , Amodiaquina/uso terapêutico , Amoxicilina/análise , Amoxicilina/normas , Amoxicilina/uso terapêutico , Antimaláricos/normas , Antimaláricos/uso terapêutico , Artemeter , Artemisininas/análise , Artemisininas/normas , Artemisininas/uso terapêutico , Medicamentos Biossimilares/normas , Medicamentos Biossimilares/uso terapêutico , Cloroquina/análise , Cloroquina/normas , Cloroquina/uso terapêutico , Resistência a Medicamentos , Instalações de Saúde , Humanos , Papua Nova Guiné , Primaquina/análise , Primaquina/normas , Primaquina/uso terapêutico , Controle de Qualidade , Quinina/análise , Quinina/normas , Quinina/uso terapêuticoRESUMO
INTRODUCTION: The emergence of drug resistance is one of the main problems concerning malaria treatment. The use of counterfeit and/or substandard antimalarial drugs can contribute to the development of parasite resistance. Thus, the aim of this study was to evaluate the quality of antimalarial drugs distributed in Brazil. METHODS: Samples containing chloroquine phosphate, mefloquine hydrochloride, primaquine phosphate, and quinine sulfate tablets were delivered to the Rio de Janeiro central storeroom (CENADI), state storerooms (SS), and Basic Health Units (BHUs) in the north region of Brazil - a total of 10 sample sets. After 5 months of storage, the samples were collected, and in vitro quality control analyses according to official and published methods were performed. RESULTS: Inadequate drug storage conditions were found in two SS and in all BHUs evaluated. There were no quality deviations found in the chloroquine samples. The quinine samples exhibited weight variation above the allowed limits. The primaquine samples were found to have packaging deficiency. The release of mefloquine in samples from some regions showed a statistically significant difference when compared with the CENADI samples. CONCLUSIONS: It is important to periodically evaluate the quality and storage conditions of essential drugs. The quality deviations found with the primaquine and quinine samples are not related to storage conditions and must be addressed urgently. The decreased mefloquine release from tablets is related to formulation problems or influenced by inadequate storage conditions, prompting further investigation. Even with the mentioned problems, the samples would probably not contribute to resistant parasite selection.
Assuntos
Antimaláricos/normas , Armazenamento de Medicamentos/normas , Medicamentos Essenciais/normas , Brasil , Cloroquina/normas , Cromatografia Líquida de Alta Pressão , Humanos , Mefloquina/normas , Primaquina/normas , Controle de Qualidade , Quinina/normasRESUMO
INTRODUCTION: The emergence of drug resistance is one of the main problems concerning malaria treatment. The use of counterfeit and/or substandard antimalarial drugs can contribute to the development of parasite resistance. Thus, the aim of this study was to evaluate the quality of antimalarial drugs distributed in Brazil. METHODS: Samples containing chloroquine phosphate, mefloquine hydrochloride, primaquine phosphate, and quinine sulfate tablets were delivered to the Rio de Janeiro central storeroom (CENADI), state storerooms (SS), and Basic Health Units (BHUs) in the north region of Brazil - a total of 10 sample sets. After 5 months of storage, the samples were collected, and in vitro quality control analyses according to official and published methods were performed. RESULTS: Inadequate drug storage conditions were found in two SS and in all BHUs evaluated. There were no quality deviations found in the chloroquine samples. The quinine samples exhibited weight variation above the allowed limits. The primaquine samples were found to have packaging deficiency. The release of mefloquine in samples from some regions showed a statistically significant difference when compared with the CENADI samples. CONCLUSIONS: It is important to periodically evaluate the quality and storage conditions of essential drugs. The quality deviations found with the primaquine and quinine samples are not related to storage conditions and must be addressed urgently. The decreased mefloquine release from tablets is related to formulation problems or influenced by inadequate storage conditions, prompting further investigation. Even with the mentioned problems, the samples would probably not contribute to resistant parasite selection.
INTRODUÇÃO: O aparecimento de resistência aos medicamentos é um dos maiores problemas do tratamento da malária. O uso de medicamentos falsos e/ou de má qualidade pode contribuir para o desenvolvimento de resistência no parasita. Este estudo tem por objetivo avaliar a qualidade dos medicamentos antimaláricos distribuídos no Brasil. MÉTODOS: Amostras contendo comprimidos de difosfato de cloroquina, cloridrato de mefloquina, difosfato de primaquina e sulfato de quinina foram enviadas ao almoxarifado central na Cidade do Rio de Janeiro (CENADI), almoxarifados estaduais (SS) e Unidades Básicas de Saúde (UBS) nos estados da região norte do Brasil, totalizando dez amostras. Após cinco meses de armazenamento, as amostras foram coletadas e analisadas segundo métodos oficiais e da literatura. RESULTADOS: Foram encontradas condições inadequadas de armazenamento de medicamentos em duas SS e em todas as UBS avaliadas. Não foram encontrados problemas de qualidade com as amostras de cloroquina. As amostras de quinina apresentaram variação de peso acima dos limites permitidos. Amostras de primaquina foram encontradas com problemas na embalagem. A cedência de mefloquina de comprimidos, em algumas regiões, apresentou diferença estatisticamente significativa quando comparada com a amostra do CENADI. CONCLUSÕES: É importante avaliar, periodicamente, a qualidade e as condições de armazenamento de medicamentos essenciais. Desvios de qualidade encontrados com as amostras de primaquina e quinina não estão relacionados às condições de armazenamento e devem ser corrigidos urgentemente. O decréscimo na cedência de mefloquina dos comprimidos está relacionado com a formulação ou foi influenciada por condições de armazenamento inadequadas, necessitando de uma investigação posterior. Apesar dos problemas mencionados, as amostras provavelmente não contribuiriam para a seleção de parasitas resistentes.
Assuntos
Humanos , Antimaláricos/normas , Armazenamento de Medicamentos/normas , Medicamentos Essenciais/normas , Brasil , Cromatografia Líquida de Alta Pressão , Cloroquina/normas , Mefloquina/normas , Primaquina/normas , Controle de Qualidade , Quinina/normasRESUMO
OBJECTIVE: The purpose of this study was to determine the pharmaceutical quality of quinine preparations sold in Nigerian markets. MATERIALS AND METHODS: The organoleptic and physicochemical properties of quinine tablets, as well as oral liquids and parenteral quinine preparations, were assessed according to British Pharmacopoeia (BP) and unofficial standards as recommended by the manufacturers. RESULTS: Of the 6 brands of tablets assessed, 4 passed the uniformity of content test and 5 the disintegration test, but only 2 the dissolution test. The pH of 2 of the 6 brands of oral liquid preparations met BP standards, while only 1 oral liquid met the BP standard for percentage content. The assay further demonstrated that 4 brands of the parenteral preparations met BP standards for quinine content. All the parenteral preparations were found to be sterile. CONCLUSION: Quinine preparations sold in Nigeria varied considerably in their pharmaceutical quality. A strict check of the quality of brands of quinine by regulatory agencies and distributors before they are sold to the public is therefore recommended.
Assuntos
Antimaláricos/normas , Quinina/normas , Administração Oral , Antimaláricos/química , Indústria Farmacêutica/normas , Humanos , Infusões Parenterais , Nigéria , Controle de Qualidade , Quinina/química , ComprimidosRESUMO
OBJECTIVE: Drug quality may be poor in many regions of the world. Our first aim was to verify whether the dose of the active compounds in various antimalarial medicines on the market in East Congo conforms to the quality requirements of the European Pharmacopoeia (Ph. Eur.). The second aim was to check the extent to which simple methods of analysis could be used to evaluate drug quality. METHODS: The formulations analysed included tablets, injections and syrups of chloroquine (CQ), quinine, sulfadoxine-pyrimethamine (SP) and proguanil. Ultraviolet (UV) spectrophotometry was used to quantify CQ and quinine in tablets and injections. Thin layer chromatography was used to identify the preservative(s) in the syrups. As the drug form (base or salt) in the tablets, is rarely declared, the estimated dose was calculated using both forms. High-performance liquid chromatography (HPLC) was used to check for assay interference and for measuring SP combinations. RESULTS AND DISCUSSION: When the dose declaration on the label was assumed to be of the salt form, 33% of CQ batches were underdosed and two of eight batches of quinine were underdosed by about 25% and 15% respectively. When the base form was assumed, only one batch of CQ tablets conformed. The underdosed batches contained about 50-66% of the claimed amount for CQ. The dose of quinine in the different batches of tablets was in the range 62-86%. For the CQ syrup, interference by the preservative Nipagin, confirmed by HPLC-UV, was observed with UV-spectrophotometry at 257 nm but not at 342 nm. The results for CQ syrup using UV-spectrophotometry at 342 nm and HPLC-UV at 257 nm were comparable and showed compliance with the European Pharmacopoeia limits of 95-105%. One of two batches of CQ injections and one of four batches of quinine injections were overdosed by about 14% and 8% respectively. The SP tablets were analysed by using HPLC-UV only. All five batches were underdosed in sulfadoxine (91-94%) but still met the United States Pharmacopeial (USP) limit of 90-110%. Two batches were slightly overdosed in pyrimethamine (106% and 108% respectively) while one batch contained neither active ingredient. The one batch of proguanil analysed, met the Ph. Eur. quality requirement (98.7%). CONCLUSION: Simple methods of analysis like UV-spectrophotometry can be used to check drug quality routinely. A substantial proportion of the antimalarial drugs sold on the Congo DR market is of poor quality. Some batches contain little or no drug. This is a serious threat to public health in the region of Congo DR.
Assuntos
Cloroquina/normas , Vigilância de Produtos Comercializados/métodos , Proguanil/normas , Pirimetamina/normas , Quinina/normas , Sulfadoxina/normas , Antimaláricos/normas , Cromatografia Líquida de Alta Pressão , República Democrática do Congo , Aprovação de Drogas , Combinação de Medicamentos , Indústria Farmacêutica/métodos , Indústria Farmacêutica/normas , Preparações Farmacêuticas/análise , Preparações Farmacêuticas/normas , Vigilância de Produtos Comercializados/normas , Controle de Qualidade , ComprimidosRESUMO
A simple, reliable HPLC method with fluorescence detection (excitation 320 and emission 388 nm) was developed and validated for quantitation of zolpidem in human plasma. Following a single-step liquid-liquid extraction, the analyte and internal standard (quinine) were separated using an isocratic mobile phase on a reversed-phase C(18) column. The lower limit of quantitation was 1.8 ng/mL, with a relative standard deviation of less than 5%. A linear dynamic range of 1.8-288 ng/mL was established. This HPLC method was validated with between-batch and within-batch precision of 1.7-4.8 and 1.2-2.3%, respectively. The between-batch and within-batch accuracy was 95.3-100.4 and 95.5-102.7%, respectively. Frequently coadministered drugs did not interfere with the described methodology. Stability of zolpidem in plasma was excellent, with no evidence of degradation during sample processing (autosampler) and 30 days storage in a freezer. This validated method is simple and repeatable enough to be used in pharmacokinetic studies.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Fluorescência , Piridinas/sangue , Humanos , Estrutura Molecular , Piridinas/química , Piridinas/farmacocinética , Quinina/análise , Quinina/normas , Padrões de Referência , Reprodutibilidade dos Testes , Espectrometria de Fluorescência , Espectrofotometria Ultravioleta , ZolpidemRESUMO
A new chemiluminescence (CL) method is proposed for the determination of quinine sulphate, which is based on the dichloromethane solvent extraction of the ion-pair complex of tetrachloroaurate (III) with quinine sulphate, and luminol CL detection in a reversed micellar medium formed by the cation surfactant cetyltrimethylammonium bromide in a dichloromethane-cyclohexane (3:7, v/v)-water (0.35 mol/L Na2CO3 buffer solution, pH 11.5). The ion-pair complex of tetrachloroaurate (III) with quinine sulphate produced an analytical CL signal when it entered the reversed micellar water pool. In optimum conditions, CL intensities are proportional to the concentrations of the studied drug over the range 0.015-10 microg/mL, with a detection limit of 1.5 ng/mL. The relative standard deviation (RSD) is 1.38% for 2.5 microg/mL quinine sulphate (n=11). The method has been applied to the determination of the studied drug in biological fluids, with satisfactory results.